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Anan Raghunath, A Pali S Hungin, David Wooff, Susan Childs
Abstract
Objectives To ascertain the prevalence of Helicobacter
pylori in patients with gastro-oesophageal reflux
disease and its association with the disease.
Design Systematic review of studies reporting the
prevalence of H pylori in patients with and without
gastro-oesophageal reflux disease.
Data sources Four electronic databases, searched to
November 2001, experts, pharmaceutical companies,
and journals.
Main outcome measure Odds ratio for prevalence of
H pylori in patients with gastro-oesophageal reflux
disease.
Results 20 studies were included. The pooled
estimate of the odds ratio for prevalence of H pylori
was 0.60 (95% confidence interval 0.47 to 0.78),
indicating a lower prevalence in patients with
gastro-oesophageal reflux disease. Substantial
heterogeneity was observed between studies. Location
seemed to be an important factor, with a much lower
prevalence of H pylori in patients with
gastro-oesophageal reflux disease in studies from the
Far East, despite a higher overall prevalence of
infection than western Europe and North America.
Year of study was not a source of heterogeneity.
Conclusion The prevalence of H pylori infection was
significantly lower in patients with than without
gastro-oesophageal reflux, with geographical location
being a strong contributor to the heterogeneity
between studies. Patients from the Far East with reflux
disease had a lower prevalence of H pylori infection
than patients from western Europe and North
America, despite a higher prevalence in the general
population.
Introduction
Gastro-oesophageal reflux disease is a common condi-
tion affecting 25-40% of the population.1 It is managed
mainly in primary care and is associated with the larg-
est prescribing cost in the NHS.2 Although there is
good evidence that infection with H pylori is the princi-
pal cause of peptic ulcer disease, there is uncertainty
about the organism’s role in gastro-oesophageal reflux
disease. Treating H pylori infection is effective in
healing duodenal ulcers.3 The effect of eradication of
the organism in patients with gastro-oesophageal
reflux disease is less clear, with some reports
suggesting that this might be counterproductive and
that H pylori infection might protect against the
disease.4 5 However, the recent Maastricht 2 guidelines
on the management of patients with H pylori infection
recommend eradication in those with gastro-
oesophageal reflux disease who are likely to require
long term proton pump inhibitor therapy.6 This is
because profound acid suppression may accelerate the
progression of H pylori induced atrophic gastritis,
increasing the potential risk of cancer.
The evidence for an association between H pylori
and gastro-oesophageal reflux disease remains mixed
and largely uncertain. Studies evaluating the presence
or absence of H pylori on gastro-oesophageal reflux
disease have often had drawbacks in design and have
given conflicting results.7 8 Fundamentally it is not cer-
tain whether there are differences in the prevalence of
H pylori between patients with and without gastro-
oesophageal reflux disease.9–13
We conducted a systematic review to establish the
overall prevalence of H pylori in patients with
gastro-oesophageal reflux disease and to determine if
this is significantly different from patients without the
disease. This is important for determining if patients
with the disease differ and to quantify the extent of
infection. This topic is also of relevance because of the
large numbers of patients in the community taking
long term proton pump inhibitors, mostly for reflux.
The determination of H pylori status in these patients
has so far not been a clinical issue; gastro-oesophageal
reflux disease is commonly diagnosed and treated in
primary care on the basis of a clinical history alone.
Methods
We included studies to November 2001 fulfilling
certain eligibility criteria (box) by searching Medline,
Embase, Cinahl, and Cochrane, using subject terms
and text words. Bibliographies of retrieved studies were
reviewed, experts in six countries and pharmaceutical
companies contacted (see bmj.com), and general
medical and major gastroenterology journals searched
over the previous year.
Assessment of eligibility and trial quality
Gastro-oesophageal reflux disease was defined accord-
ing to published definitions.14–17 These comprised two
categories, both in patients who had heartburn or
reflux as the predominant symptoms. The first was the
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presence of endoscopically defined oesophagitis and
the second, when endoscopy did not show oesoph-
agitis, a positive result for pH monitoring with or with-
out oesophagitis on histology.
Two investigators independently reviewed the
papers according to the predefined criteria (see box).
Abstracts were included only if they met the eligibility
criteria. Disagreements were resolved by consensus
with a third reviewer. Quality assessments focused on
whether the methods for obtaining cases and controls,
data collection, and H pylori testing were stated.
Data extraction
AR collated data from eligible studies on standardised
forms, which were checked by SC. Data on the
prevalence ofH pylori in various grades of oesophagitis
and the absence of visible reflux disease on endoscopy
were recorded as reported, but for analysis the overall
prevalence of H pylori in gastro-oesophageal reflux dis-
ease was used.
Data synthesis
Each of the 20 included studies was summarised
according to its odds ratio, with an odds ratio of less
than one indicating a higher prevalence of H pylori
among controls than among patients with gastro-
oesophageal reflux disease. Results were pooled with a
fixed effect (Mantel-Haenszel) model, which was
assessed with a test of homogeneity and a funnel plot.18
Odds ratios were pooled with a random effects model
in cases of substantial heterogeneity.19 The statistical
analysis was performed with the free package R, and
the rmeta subpackage contributed by Thomas Lumley
(University of Washington).20
Results
Our initial search identified 654 articles, but only 45
evaluated the prevalence of H pylori in patients with
gastro-oesophageal reflux disease. Thirty seven of
these met the eligibility criteria; 16 were excluded after
further scrutiny (see table A on bmj.com),7 9 13 21–33 and
one was excluded because of overlap with a study by
the same lead author (the proportions between the two
studies were so close that there was virtually no differ-
ence in results; see table A on bmj.com).34 35 This left 20
studies for review, totalling 4134 patients, of whom
58.5% (n=2418) were in control groups (table).10 35–53
Prevalence of H pylori infection
The average prevalence of H pylori infection in patients
with gastro-oesophageal reflux disease was 38.2%
(range 20.0-82.0%) compared with 49.5% (29.0-75.6%)
in the comparator group. Four studies showed a higher
prevalence of H pylori infection among patients with
gastro-oesophageal reflux disease, but not significantly
so (fig 1 and table B on bmj.com).36 39 46 47 The remain-
ing studies showed a lower prevalence among patients
with gastro-oesophageal reflux disease, significantly so
in six studies.10 35 42 45 49 53 The pooled odds ratio was
0.58 (95% confidence interval 0.51 to 0.66), indicating
a lower prevalence of H pylori infection among patients
with gastro-oesophageal reflux disease (heterogeneity
test: 2=83.01, df=19, P < 0.001).
We found no clear evidence of publication bias (fig
2): nor would any be expected in this context. Because
of the presence of substantial heterogeneity, the studies
were pooled with the DerSimonian-Laird random
effects model (summary odds ratio 0.60, 0.47 to 0.78),
which showed weaker but still strong evidence of a
lower prevalence of H pylori infection among patients
with gastro-oesophageal reflux disease.
Statistical heterogeneity was investigated by year of
study (no effect) and by location. Five studies were of
patients from the Far East,35 42 45 49 53 seven of patients
from North America,37 38 40 48 50–52 and seven of patients
from western Europe.10 40 42 44 45 47 48 One further study
originated from Chile.36 Some similarities were found
in results for studies from particular geographical
locations (fig 1). When the three main groups were
analysed separately, the results for western Europe
gave an odds ratio of 0.76 (0.61 to 0.96) and a test for
heterogeneity of 2=14.01, df=6, P=0.030. One study
seemed to dominate the analysis, but repeating the
analysis after excluding this study gave an odds ratio of
Eligibility and quality criteria for inclusion in
systematic review
Studies with a comparator, control, or reference
group
Patients with gastro-oesophageal reflux disease should
have undergone gastroscopy.
• Included:
• Patients with endoscopically proved oesophagitis
• Patients with normal appearance of oesophagus on
endoscopy and with confirmation of
gastro-oesophageal reflux disease either by pH studies
or histology
• Excluded:
• Patients with non-ulcer dyspepsia in whom other
confirmation of gastro-oesophageal reflux disease by
pH studies or histology of the oesophagus was not
available
• Patients with normal endoscopy result and typical
reflux symptoms but confirmation by pH studies or
histology not available or confirmed
• Patients known or discovered to have Barrett’s
oesophagus
• Patients with confirmed peptic ulcer disease
• Patients who had received proton pump inhibitors
within the previous two weeks or undergone
eradication of H pylori
Comparator group (one or more of the following)
• Normal endoscopy result and absence of symptoms
of gastro-oesophageal reflux disease
• Healthy asymptomatic volunteers
• Absence of pathological reflux on pH
monitoring—that is, oesophageal pH is < 4 for more
than 3.5% of total recorded time, or as defined by
author of the study
• Normal endoscopy result and absence of
oesophagitis on histology
Quality criteria
• Documentation of how cases were obtained
• Appropriateness of comparator
• Similar data collection for cases and comparator
group
• Similar H pylori testing for cases and comparator
group
• Basic data adequately described
• Statistical methods described and significance levels
assessed
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Studies included in systematic review
Reference Type of study Participants Intervention Outcome Comments or conclusions
Werdmuller and
Loffeld 199710
Descriptive,
prospective
Consecutive patients undergoing
endoscopy of upper gastrointestinal
tract for upper abdominal symptoms
or reflux symptoms. Cases (n=240, of
which 118 patients with proved
gastro-oesophageal reflux disease
included). Rest with hiatus hernia and
no reflux oesophagitis or with
Barrett’s oesophagus excluded.
Reference group (n=399): normal
endoscopy and presumed absence of
typical reflux symptoms
Endoscopy of upper gastrointestinal
tract, H pylori testing by histology
(haematoxylin and eosin stain),
culture, quick urease test, and
serology (not all tests in every patient)
H pylori prevalence in patients with
gastro-oesophageal reflux disease
(29%) and reference group (51%)
We assumed from details that
patients in reference group do not
have reflux disease
Koike et al 199935 Case-control,
prospective
Patients were self referred and
referred by doctor. Cases (n=175):
patients with reflux oesophagitis.
Controls: age-sex matched, randomly
selected, who visited hospital, were
asymptomatic, and had normal
endoscopy results
Endoscopy of upper gastrointestinal
tract. H pylori testing by histology,
rapid urease test, and serology.
Atrophic gastritis assessed by updated
Sydney system, and serum
pepsinogen measured
H pylori prevalence in patients with
gastro-oesophageal reflux disease
(34%) and controls (72%)
Csendes et al 199736 Case-control,
prospective, prevalence
study
Cases (n=136): patients with chronic
gastro-oesophageal reflux disease
(reflux oesophagitis, negative reflux
disease on endoscopy) symptoms of
at least three years’ duration. Controls
(n=190): patients needing endoscopy,
none of whom had symptoms of
gastro-oesophageal reflux disease
Endoscopy of upper gastrointestinal
tract in cases and controls, H pylori
testing by histology, pH-metry in all
cases of gastro-oesophageal reflux
disease, no pH-metry in controls
H pylori prevalence in patients with
reflux oesophagitis, reflux disease
negative on endoscopy, Barrett’s
oesophagus, and controls. No
significant difference in H pylori
prevalence between patients with
patients with reflux oesophagitis
(32%), reflux disease negative on
endoscopy (25%), and controls
(29%). Also no difference in age and
sex distribution between reflux
patients and controls
Exclusion of peptic ulcer not
clearly stated
El-Serag et al 199937 Descriptive,
prospective
Patients referred for elective
endoscopy of upper gastrointestinal
tract. Cases (n=154, of which 116
patients were included, 38 excluded
because of Barrett’s oesophagus): all
patients with erosive oesophagitis.
Controls (n=148): Patients with
normal endoscopy result and absence
of symptoms of gastro-oesophageal
reflux disease
Endoscopy of upper gastrointestinal
tract in cases and controls, H pylori
testing by haematoxylin and eosin
stain
H pylori prevalence in patients with
gastro-oesophageal reflux disease
(31%) and controls (43%)
This study looked at protective
effect of corpus gastritis against
reflux oesophagitis. We excluded
Barrett’s oesophagus from our
analysis
Fallone et al 200038 Descriptive,
prospective.
Patients scheduled for endoscopy of
upper gastrointestinal tract. Cases
(n=327, of which 81 patients with
gastro-oesophageal reflux disease
included). Rest were classified into
non-ulcer disease, duodenal ulcer,
gastric ulcer, and therefore excluded.
Patients with gastro-oesophageal
reflux disease had reflux oesophagitis
or negative reflux disease on
endoscopy. Comparator group (n=78):
patients in whom there were no
symptoms of gastro-oeosophageal
reflux disease and in whom
indications for endoscopy were
multiple. All had normal oesophagus
or findings unrelated to
gastro-oesophageal reflux disease
Endoscopy of upper gastrointestinal
tract; H pylori testing by histology and
culture; detection of specific genes or
gene sequence within H pylori and
detection of CagA antibodies
H pylori prevalence in patients with
gastro-oesophageal reflux disease
(33%) and comparator group (48%).
Prevalence of CagA, CagE, vacA S1
genotypes, and CagA antibody
determined in cases and comparator
group
Some patients with reflux disease
negative on endoscopy but reflux
not proved may have been
included in our prevalence data.
This study concluded that
gastro-oesophageal reflux disease
was associated with a significantly
lower rate of vacA S1 genotype
than in controls
Gisbert et al 200139 Descriptive,
prospective, prevalence
Consecutive patients undergoing 24
hour oesophageal pH monitoring in
motility unit because of symptoms
suggestive of gastro-oesophageal
reflux disease. Cases (n=56): typical
symptoms of gastro-oesophageal
reflux disease and positive pH
findings. Controls (n=44): symptoms
of gastro-oesophageal reflux disease
but negative pH findings
Endoscopy of upper gastrointestinal
tract, 24 hour oesophageal pH
monitoring and H pylori testing by
histology and rapid urease test
H pylori prevalence in patients with
gastro-oesophageal reflux disease
(57%) and controls (52%)
Comparator group may represent
patients with non-ulcer dyspepsia
Goldblum et al 199840 Case-control,
prospective
Cases (n=58): patients with classic
symptoms of gastro-oesophageal
reflux disease enrolled into study.
Controls (n=27): patients undergoing
endoscopy for reasons other than
symptoms of gastro-oesophageal
reflux disease, Barrett’s oesophagus,
peptic ulcer disease, or dyspepsia
Endoscopy of upper gastrointestinal
tract in cases and controls; H pylori
testing by histology (haematoxylin and
eosin and Giemsa stain) and serology
H pylori prevalence in patients with
gastro-oesophageal reflux disease
(41%) and controls (48%). Prevalence
of carditis and intestinal metaplasia of
cardia in cases and controls also
determined
This study also concluded that
cardia inflammation and cardia
intestinal metaplasia are associated
with H pylori infection
Hacklesberger et al
199841
Case-control,
prospective
Cases (130 of 171 included,
remaining 41 had associated peptic
ulcer disease): consecutive Caucasian
patients undergoing elective
endoscopy. Controls (n=227):
asymptomatic volunteers or patients
attending for other reasons and
without any symptoms of
gastro-oesophageal reflux disease
Endoscopy of upper gastrointestinal
tract in cases only. H pylori testing by
histology and rapid urease test in
cases, 13-carbon urease breath test
H pylori prevalence in patients with
gastro-oesophageal reflux disease
(38%) and controls (39%)
Different methods of H pylori
testing in cases and controls. No
endoscopy in controls
Haruma et al 200042 Retrospective
case-control
Of 6205 patients undergoing
endoscopy of upper gastrointestinal
tract between defined periods, 229
were defined as having reflux
oesophagitis. Of these, 95 met
authors’ inclusion criteria. Controls
(n=190): healthy, asymptomatic,
age-sex matched selected from among
608 healthy individuals who had
undergone routine healthcare check
for gastric cancer
Endoscopy of upper gastrointestinal
tract in cases and controls; H pylori
testing by Giemsa stain and serology.
Inflammation, atrophy, and intestinal
metaplasia were evaluated using
updated Sydney system. Serum
gastrin and pepsinogen concentrations
determined
H pylori prevalence in patients with
gastro-oesophageal reflux disease
(41%) and controls (76%)
The authors found significant low
prevalence of H pylori in patients
over 60 but not under 59 with
reflux oesophagitis, when
compared with age-sex matched
controls
Liston et al 199643 Descriptive,
prospective, prevalence
Consecutive patients admitted for
gastroscopy recruited regardless of
reasons for procedure. Main reasons
were anaemia, reflux symptoms, and
epigastric pains. Cases (n=37): reflux
oesophagitis (macroscopic or
microscopic). Comparator group
(n=33): normal endoscopy result and
no evidence of histological
oesophagitis
Endoscopy of upper gastrointestinal
tract; H pylori testing by histology,
rapid urease test, serology, and
13-carbon urease breath test
H pylori prevalence in patients with
reflux oesophagitis (76%) and
comparator group (82%). Patterns of
gastritis described in the two groups
Although exclusion of patients
with peptic ulcer disease had not
been clearly stated, on reading the
paper, we assumed this to be the
case
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Studies included in systematic review contd
Reference Type of study Participants Intervention Outcome Comments or conclusions
Manes et al 199944 Case-control,
prospective, prevalence
Cases (105 of 202, of which 105
patients with proved
gastro-oesophageal reflux disease
included): consecutive patients with
typical symptoms of
gastro-oesophageal reflux disease
lasting more than six months. Peptic
ulcer cases excluded. Controls
(n=200): healthy asymptomatic blood
donors and patients with functional
non-specific abdominal problems with
normal endoscopy result except for
signs of chronic gastritis
Endoscopy of upper gastrointestinal
tract in cases only. H pylori testing by
histology or rapid urease test in cases
and serology in controls
H pylori prevalence in patients with
erosive reflux oesophagitis (32%),
reflux disease negative on endoscopy
(62%), and control group (40%). Also
patterns of gastritis, H pylori
colonisation, and dyspepsia symptoms
in patients with reflux disease
negative on endoscopy and reflux
oesophagitis compared
We excluded patients with
Barrett’s oesophagus (as stated in
our protocol) and also reflux
disease negative on endoscopy
(not proved to have
gastro-oesophageal reflux disease)
from our analysis. Different
methods of H pylori testing in
cases and controls, no endoscopy
in controls
Mihara et al 199645 Case-control,
prospective, prevalence
Cases (n=70): patients with reflux
oesophagitis. Controls (n=70): age-sex
matched, no symptoms of
gastro-oesophageal reflux disease and
normal endoscopy result
Endoscopy of upper gastrointestinal
tract, H pylori testing by Giemsa stain
and serology, gastritis and atrophy
scores, and serum pepsinogen levels
H pylori prevalence in patients with
gastro-oesophageal reflux disease
(37%) and controls (67%). Gastritis,
atrophy scores, and serum
pepsinogen 1, pepsinogen 2 levels
and ratios in cases and controls also
determined
Abstract
Newton et al 199746 Case-control,
prospective, prevalence
Cases (83, of which 25 patients with
proved gastro-oesophageal reflux
disease included): patients referred for
endoscopy divided into four groups.
(reflux oesophagitis, duodenal ulcer,
or both, and Barrett’s oesophagus).
Controls (n=25): asymptomatic
patients with anaemia referred for
endoscopy
Endoscopy of upper gastrointestinal
tract in cases and controls. H pylori
testing by histology and CLO test
H pylori prevalence in patients with
gastro-oesophageal reflux disease
(42%) and controls (36%). H pylori
colonisation and distribution assessed
in different patient groups
We excluded patients with
Barrett’s oesophagus, duodenal
ulcer, and duodenal ulcer with
reflux oesophagitis from our
analysis
Pieramico and Zanetti
200047
Case-control,
prospective
Cases (122, of which 54 patients with
proved gastro-oesophageal reflux
disease included, 68 patients with
negative reflux disease on endoscopy
excluded because reflux not proved):
consecutive patients referred for
gastro-oesophageal reflux disease
symptoms to endoscopy unit.
Controls (n=49): patients who
underwent endoscopy in same period
as cases for reasons other than
symptoms of gastro-oesophageal
reflux disease, Barrett’s oesophagus,
active or previous peptic ulcer
disease, gastric or oesophageal
neoplasms, or dyspepsia
Endoscopy of upper gastrointestinal
tract in cases and controls; H pylori
testing by Giemsa stain in cases and
controls
H pylori prevalence in patients with
gastro-oesophageal reflux disease
(44%) and controls (38%)
Grade 0 (reflux disease negative
on endoscopy, 68 patients) were
not proved to have
gastro-oesophageal reflux disease,
hence we excluded them from our
analysis
Schubert and Schnell
198948
Descriptive,
prospective
All consenting patients referred for
endoscopy between defined periods.
Cases (170, of which 31 patients with
proved gastro-oesophageal reflux
disease included). Rest were classified
into several diagnostic groups
(duodenal ulcer, gastric ulcer,
non-ulcer dyspepsia, gastritis,
duodenitis) and therefore excluded.
Control or comparator group (n=42):
patients with absence of symptoms of
gastro-oesophageal reflux disease and
normal endoscopy result
Endoscopy of upper gastrointestinal
tract; H pylori testing by histology,
rapid urease test, and culture
H pylori prevalence in patients with
gastro-oesophageal reflux disease
(26%) and comparator group (40%)
Some patients with reflux disease
negative on endoscopy but reflux
not proved may have been
included in our prevalence data
Shirota et al 199949 Descriptive,
retrospective
Random selection of cases and
controls from patients who underwent
endoscopy of upper gastrointestinal
tract between defined periods. Cases
(n=73): reflux oesophagitis (mild,
severe). Controls (n=28): normal
endoscopy result and presumed
absence of symptoms of
gastro-oesophageal reflux disease
Endoscopy of upper gastrointestinal
tract, H pylori testing by culture,
urease test, and serology, serum
pepsinogen levels, and oesophageal
manometry
H pylori prevalence in patients with
gastro-oesophageal reflux disease
(36%) and controls (61%).
Pepsinogen 1 to pepsinogen 2 ratios
determined to assess severity of
atrophic gastritis
We assumed from details that
patients in control group did not
have symptoms of
gastro-oesophageal reflux disease.
Authors concluded that low
prevalence of H pylori might result
in milder grade of atrophic
gastritis and consequently
exacerbate reflux oesophagitis
Vaezi et al 200050 Descriptive,
prospective
Patients undergoing endoscopy of
upper gastrointestinal tract. Based on
questionnaire before endoscopy and
endoscopy findings, patients were
grouped into cases:
gastro-oesophageal reflux disease
(n=108), short and long-segment
Barrett’s oesophagus, and controls
(n=60). Controls had normal
endoscopy and no symptoms of
gastro-oesophageal reflux disease
Endoscopy of upper gastrointestinal
tract. H pylori testing by Giemsa stain,
serology to determine IgG response to
H pylori whole cell antigen and to
CagA using enzyme linked
immunosorbent assay
H pylori and CagA prevalence in cases
(gastro-oesophageal reflux disease,
short segment and long segment
Barrett’s oesophagus) and controls. H
pylori prevalence in patients with
gastro-oesophageal reflux disease
(36%) and controls (42%)
Authors concluded that CagA
positive H pylori strains might
protect against Barrett’s
oesophagus. We excluded patients
with Barrett’s oesophagus from
our analysis
Varanasi et al 199851 Descriptive,
retrospective
Review of records of all patients (>18
years) who had endoscopy of upper
gastrointestinal tract and rapid urease
testing. Cases (n=54):
gastro-oesophageal reflux disease
(reflux oesophagitis or proved
negative reflux disease on endoscopy,
typical symptoms of
gastro-oesophageal reflux disease,
normal endoscopy, and histological
esophagitis) and Barrett’s
oesophagus. Comparator (n=257):
normal endoscopy and presumed
absence of symptoms of
gastro-oesophageal reflux disease
Endoscopy of upper gastrointestinal
tract; H pylori testing by rapid urease
test in all, histopathology and
serology in some
H pylori prevalence in patients with
and without gastro-oesophageal reflux
disease as well as stratifying for
presence or absence of peptic ulcer
disease in each group. H pylori
prevalence in patients with
gastro-oesophageal reflux disease
(29%) and controls (34%)
We excluded patients with
Barrett’s oesophagus and cases of
reflux oesophagitis associated with
peptic ulcer disease from our
analysis. Authors found no
variability of H pylori between
different groups of patients with
reflux oesophagitis
Vicari et al 199852 Prospective,
case-control
Cases: patients with classic symptoms
of gastro-oesophageal reflux disease
(153, of which 84 patients included
and 59 with Barrett’s oesophagus
excluded) enrolled into study.
Controls: patients undergoing
endoscopy for reasons other than
symptoms of gastro-oesophageal
reflux disease, Barrett’s oesophagus,
peptic ulcer disease, or dyspepsia
Endoscopy of upper gastrointestinal
tract in cases and controls; H pylori
testing by histology (haematoxylin and
eosin and Giemsa stain) and serology
H pylori prevalence in patients with
gastro-oesophageal reflux disease
(36%) and controls (46%). CagA
positivity status also determined in
cases and controls
Some patients with reflux disease
negative on endoscopy but reflux
not proved may have been
included in our prevalence data.
We excluded patients with
Barrett’s oesphagus from our
analysis
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0.97 (0.75 to 1.27) and a test for heterogeneity of
2=1.8, df=5, P=0.88.10 The evidence for western Europe
is therefore equivocal.
Consistent evidence was found for a lower
prevalence of H pylori infection among both North
American patients with gastro-oesophageal reflux dis-
ease (odds ratio 0.70, 0.55 to 0.9; test for heterogeneity,
2=0.92, df=6, P=0.99) and patients from the Far East
with gastro-oesophageal reflux disease (0.24, 0.19 to
0.32 and 2=2.36, df=4, P=0.670). A single study from
South America found a higher prevalence.36 Differ-
ences in location may explain much of the heterogen-
eity among the studies. Some of the remaining
heterogeneity may be a product of clinical
heterogeneity—for example, differences in methods of
H pylori testing, pH measurements, and endoscopic
classification of oesophagitis.54
Discussion
Our systematic review found a significantly lower
prevalence of H pylori infection among patients with
gastro-oesophageal reflux disease than among those
without the disease, geographical location being an
important determinant. Although the results we found
were based on studies with a comparator group, there
were significant differences between study design (pro-
spective or retrospective case-control, trial), study
population, identification of cases and controls,
inclusion and exclusion criteria, matching of cases and
controls, and methods of testing for H pylori. Our
results therefore need to be interpreted with caution.
Most of the participants underwent endoscopy for
clinical reasons and thus did not constitute a
population group as such, although we discovered
three community based studies.41 42 44 Ascertaining the
prevalence of H pylori thus depended on a proportion
of patients who were being investigated for suspected
lesions. This is unlikely to have substantially compro-
mised our results because we excluded patients with
symptoms of gastro-oesophageal reflux disease who
had negative results for endoscopy or pH testing.
Given that there was substantial heterogeneity
between the studies, we acknowledge issues about the
appropriateness of reporting a pooled odds ratio. On
further exploration we did find a possible difference
between the Far East and North America or western
Europe in prevalence of H pylori infection in patients
with gastro-oesophageal reflux disease; a single study
Chile, Csendes et al 199736
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   Newton et al 199746
   Pieramico and Zanetti 200047
   Gisbert et al 200139
   Hackelsberger et al 199841
   Manes et al 199944
   Liston et al 199643
   Werdmuller and Loffeld 199710
North America
   Vaezi et al 200050
   El-Serag et al 199937
   Goldblum et al 199840
   Varanasi et al 199851
   Vicari et al 199852
   Schubert and Schnell 198948
   Fallone et al 200038
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   Shirota et al 199949
   Wu et al 199953
   Mihara et al 199645
   Haruma et al 200042
   Koike et al35
Summary
Study Reference
0.10 0.16 0.25 0.40 0.63 1.00
Odds ratio
1.58 2.51 3.98
Fig 1 Odds ratios (95% confidence intervals) for prevalence of H
pylori infection, grouped by geographical location. Large boxes
indicate studies with small standard errors (essentially larger sample
sizes) and vertical dotted line indicates no difference between groups
Studies included in systematic review contd
Reference Type of study Participants Intervention Outcome Comments or conclusions
Wu et al 199953 Case-control,
prospective.
Cases (106, of which we included 66
and excluded 40 with reflux disease
negative on endoscopy in whom
diagnosis of reflux disease was not
proved): Patients with typical
symptoms of gastro-oesophageal
reflux disease and reflux oesophagitis.
Controls (n=120): absence of
symptoms of gastro-oesophageal
reflux disease, absence of dyspepsia,
and recruited from general medical
clinics and day care centres without
any evidence of gastrointestinal
disease
Endoscopy of upper gastrointestinal
tract in H pylori positive cases, H
pylori testing by serology in cases and
controls, Giemsa stain for H pylori,
haematoxylin and eosin stain for
gastritis, and intensity of inflammation
and bacterial colonisation by the
updated Sydney system in H pylori
positive cases
H pylori prevalence in patients with
gastro-oesophageal reflux disease
(32%) and controls (61%).
Histological assessment of gastritis
and H pylori colonisation in patients
with gastro-oesophageal reflux
disease also studied
We excluded patients with reflux
disease negative on endoscopy
from our analysis
Effect
Si
ze
-1.5 -1.0 -0.5 0.0 0.5
Fig 2 Size and effect of results from eligible studies of prevalence of
H pylori infection in patients with and without gastro-oesophageal
reflux disease
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from South America gave a higher prevalence.36 This
seems to indicate that the prevalence of H pylori in
patients with gastro-oesophageal reflux disease is
lower in countries where the prevalence of H pylori in
the general population is high. Reasons are unclear
and may be related to dietary or genetic factors. Four
studies reported a higher prevalence among patients
with gastro-oesophageal reflux disease, but in only one
was the difference significant.36 Reasons are uncertain
but may partly be related to factors such as study
design, selection of cases and controls, and method of
testing for H pylori. Again, presenting data as pooled
estimates of odds ratios for geographical locations may
give the impression of post hoc confirmatory analyses,
but we strongly believe that there is a location effect
evident in these data and that the prevalence has
different patterns within locations.
We did not separately analyse the prevalence of H
pylori infection in males and females. These data were
not obtainable in many studies and, when available,
there was no reported difference.We excluded patients
with Barrett’s oesophagus because we thought that this
condition merited a systematic review in its own right.
The clinical relevance of a lower prevalence of H
pylori in patients with gastro-oesophageal reflux
disease is unclear. Some studies have shown that H
pylori may be protective against gastro-oesophageal
reflux disease and that infected patients may have a less
severe form of the disease.4 5 Evidence is also
conflicting on the effect of H pylori infection on the
efficacy of proton pump inhibitors. One study found
that patients with gastro-oesophageal reflux disease
and H pylori infection responded significantly better to
proton pump inhibitors than those without the
infection.8 Another trial found that patients not
infected with H pylori did not need higher doses of acid
suppression with proton pump inhibitors to stay in
remission.7 Evidence shows that H pylori induces
atrophic gastritis in the presence of long term acid
suppression with proton pump inhibitors, and recent
guidelines have advocated eradication of H pylori in
patients receiving long term proton pump therapy.6 55
We are unable to definitively comment on the ben-
efit or possible detriment of H pylori eradication in
patients with gastro-oesophageal reflux disease; a
further review of this is in preparation. Our findings
add insight into the complex relation between H pylori
infection and gastro-oesophageal reflux disease.
Clearly, more, well designed, prospective, large scale,
case-control studies and trials are required to
determine the epidemiological relation between H
pylori and gastro-oesophageal reflux disease and the
clinical implications of this association.
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